Lilly’s Zepbound Cuts Risk of Diabetes

Lilly’s Zepbound Cuts Risk of Diabetes

42:442024-08-20

Om episode

Watch Alix and Paul LIVE every day on YouTube: http://bit.ly/3vTiACF. Sam Fazeli, Bloomberg Intelligence, Director of Research for Global Industries and Senior Pharmaceuticals, discusses how Eli Lilly’s drug Zepbound, cuts the risk of diabetes. Craig Trudell, Bloomberg Global Autos Editor, discusses the European Union saying it plans to introduce an additional 9% tariff on Teslas imported from China. Dryden Pence, CIO at Pence Wealth Management, joins to discuss his outlook for the markets. Henri Pierre-Jacques, Co-founder & Managing Partner, at Harlem Capital Partners, discusses current investments in AI. Katerina Simonetti, Senior Vice President, Private Wealth Advisor of Morgan Stanley Private Wealth Management, discusses her outlook on the markets, investing.Hosts: Paul Sweeney and Alix SteelSee omnystudio.com/listener for privacy information.

Oppdag

Mer

  • Om informasjonskapsler
  • Generelle vilkår
  • Personvernerklæringexternal link
logo
redaktorsansvar

Podme arbeider etter Vær Varsom-plakatens regler for god presseskikk. Ansvarlig redaktør og daglig leder er Kristin Ward Heimdal. Redaktør for eksterne innholdssamarbeid er Mathias Thaulow Lisberg.

© Podme AB 2025